US4741900A
(en)
|
1982-11-16 |
1988-05-03 |
Cytogen Corporation |
Antibody-metal ion complexes
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
Geänderte antikörper.
|
DE68921982T4
(de)
|
1988-06-14 |
1996-04-25 |
Cetus Oncology Corp |
Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
|
US5149782A
(en)
|
1988-08-19 |
1992-09-22 |
Tanox Biosystems, Inc. |
Molecular conjugates containing cell membrane-blending agents
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
US5108921A
(en)
|
1989-04-03 |
1992-04-28 |
Purdue Research Foundation |
Method for enhanced transmembrane transport of exogenous molecules
|
ZA902949B
(en)
|
1989-05-05 |
1992-02-26 |
Res Dev Foundation |
A novel antibody delivery system for biological response modifiers
|
CA2018248A1
(fr)
|
1989-06-07 |
1990-12-07 |
Clyde W. Shearman |
Anticorps monoclonaux contre le recepteur alpha-beta de cellules t humaines, leur production et leur utilisation
|
US5314995A
(en)
|
1990-01-22 |
1994-05-24 |
Oncogen |
Therapeutic interleukin-2-antibody based fusion proteins
|
JP3319594B2
(ja)
|
1990-03-20 |
2002-09-03 |
ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク |
定常領域の代わりに受容体結合性リガンドを有するキメラ抗体
|
ES2108048T3
(es)
|
1990-08-29 |
1997-12-16 |
Genpharm Int |
Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
|
ATE218889T1
(de)
|
1990-11-09 |
2002-06-15 |
Stephen D Gillies |
Cytokine immunokonjugate
|
EP0519596B1
(fr)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
|
ATE207080T1
(de)
|
1991-11-25 |
2001-11-15 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
US5429746A
(en)
|
1994-02-22 |
1995-07-04 |
Smith Kline Beecham Corporation |
Antibody purification
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
UA71889C2
(uk)
|
1996-04-02 |
2005-01-17 |
Йєда Рісерч Енд Дівелопмент Ко. Лтд. |
Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
|
CA2262405A1
(fr)
|
1996-08-02 |
1998-02-12 |
Bristol-Myers Squibb Company |
Procede servant a inhiber la toxicite provoquee par les immunoglobulines provenant de l'utilisation d'immunoglobulines en therapie et en diagnostic in vivo
|
WO1998023289A1
(fr)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
Modulation de la fixation de l'igg au fcrn
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
AU736549B2
(en)
|
1997-05-21 |
2001-08-02 |
Merck Patent Gesellschaft Mit Beschrankter Haftung |
Method for the production of non-immunogenic proteins
|
JP2002510481A
(ja)
|
1998-04-02 |
2002-04-09 |
ジェネンテック・インコーポレーテッド |
抗体変異体及びその断片
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
WO2000009560A2
(fr)
|
1998-08-17 |
2000-02-24 |
Abgenix, Inc. |
Production de molecules modifiees avec demi-vie serique prolongee
|
EP1006183A1
(fr)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Récepteurs Fc recombinantes et solubles
|
CN1202128C
(zh)
|
1998-12-08 |
2005-05-18 |
拜奥威神有限公司 |
修饰蛋白的免疫原性
|
PL209786B1
(pl)
|
1999-01-15 |
2011-10-31 |
Genentech Inc |
Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
ES2649037T3
(es)
|
2000-12-12 |
2018-01-09 |
Medimmune, Llc |
Moléculas con semividas prolongadas, composiciones y usos de las mismas
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
US20040018557A1
(en)
|
2002-03-01 |
2004-01-29 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
GB0216648D0
(en)
|
2002-07-18 |
2002-08-28 |
Lonza Biologics Plc |
Method of expressing recombinant protein in CHO cells
|
ATE536188T1
(de)
|
2002-08-14 |
2011-12-15 |
Macrogenics Inc |
Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
|
ATE541857T1
(de)
|
2002-09-27 |
2012-02-15 |
Xencor Inc |
Optimierte fc-varianten und herstellungsverfahren dafür
|
JP4768439B2
(ja)
|
2002-10-15 |
2011-09-07 |
アボット バイオセラピューティクス コーポレイション |
変異誘発による抗体のFcRn結合親和力又は血清半減期の改変
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス,インコーポレーテッド |
変異型Fc領域を含む抗体の同定および作製ならびにその利用法
|
AU2004266159A1
(en)
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Improved antibodies having altered effector function and methods for making the same
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
WO2005047327A2
(fr)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
|
US20050249723A1
(en)
|
2003-12-22 |
2005-11-10 |
Xencor, Inc. |
Fc polypeptides with novel Fc ligand binding sites
|
BRPI0506771A
(pt)
|
2004-01-12 |
2007-05-22 |
Applied Molecular Evolution |
anticorpo, e, composição farmacêutica
|
AU2005227326B2
(en)
|
2004-03-24 |
2009-12-03 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
WO2005123780A2
(fr)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Modification des affinites de liaison pour le fcrn ou de la demi-vie serique d'anticorps par mutagenese
|
WO2006085967A2
(fr)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
Anticorps monoclonaux optimises anti-cd20 a variants fc
|
EP3342782B1
(fr)
|
2004-07-15 |
2022-08-17 |
Xencor, Inc. |
Variantes optimisées de fc
|
WO2006047350A2
(fr)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
Variants d'immunoglobuline igg a fonction effectrice optimisee
|
UY34317A
(es)
*
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
WO2015066379A2
(fr)
*
|
2013-10-30 |
2015-05-07 |
Genzyme Corporation |
Procédés d'amélioration de thérapie immuno-suppressive par des administrations multiples de polypeptide de liaison au tcr alpha-bêta
|